2013
DOI: 10.1001/2013.jamaophthalmol.91
|View full text |Cite
|
Sign up to set email alerts
|

Ranibizumab for Edema of the Macula in Diabetes Study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
46
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 135 publications
(48 citation statements)
references
References 6 publications
0
46
0
Order By: Relevance
“…Recently, the advent of anti-VEGF drugs and their excellent results in clinical studies on both diabetic macular edema (DME) [21,22,23] and PDR [24,25] support the hypothesis raised by previous studies that inhibition of VEGF overexpression may lead to effective treatment of these conditions [16,17,18,19]. In addition to drug therapy, it has been proposed that macular focal/grid lasering may reduce the number of required injections of anti-VEGF drugs to resolve DME [21,26].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Recently, the advent of anti-VEGF drugs and their excellent results in clinical studies on both diabetic macular edema (DME) [21,22,23] and PDR [24,25] support the hypothesis raised by previous studies that inhibition of VEGF overexpression may lead to effective treatment of these conditions [16,17,18,19]. In addition to drug therapy, it has been proposed that macular focal/grid lasering may reduce the number of required injections of anti-VEGF drugs to resolve DME [21,26].…”
Section: Discussionmentioning
confidence: 99%
“…In addition to drug therapy, it has been proposed that macular focal/grid lasering may reduce the number of required injections of anti-VEGF drugs to resolve DME [21,26]. Gaucher et al [20] also reported spontaneous resolution of DME after extensive PRP of florid PDR without focal/grid laser treatment or intravitreal injection of anti-VEGF drugs.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…At month 36 BCVA improvement in the ranibizumab group was 10.3 letters compared with 7.2 letters at month 24 whereas no statistically significant improvement was found for the laser and laser + ranibizumab groups. However, edema resolution occurred more in the laser and ranibizumab + laser groups [34]. …”
Section: Ranibizumabmentioning
confidence: 99%
“…Many earlier studies predicted that an inhibition of vascular endothelial growth factor (VEGF) overexpression was the key to effective treatment for DME and DR [8,9,10,11,12], which has since been confirmed by the advent of anti-VEGF drugs and their excellent results in clinical studies of DME [13,14,15]. While conventional focal/grid laser therapy, which has long been the gold standard for DME treatment, cannot be used for DME within 500 µm of the fovea, anti-VEGF drugs are capable of reducing fovea-involving DME and are likely to become the first-line treatment for DME [13,14,15].…”
Section: Introductionmentioning
confidence: 99%